(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 October 2013 (03.10.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/147462 A1

(51) International Patent Classification:
A61K 31/4178 (2006.01) *A61K 9/20* (2006.01)
A61K 31/505 (2006.01) *A61K 9/48* (2006.01)

(21) International Application Number:
PCT/KR2013/002378

(22) International Filing Date:
22 March 2013 (22.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2012-0032903 30 March 2012 (30.03.2012) KR

(71) Applicant: **DAEWOONG PHARMACEUTICAL CO., LTD.** [KR/KR]; 223-23, Sangdaewon-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do 462-120 (KR).

(72) Inventors: **CHANG, Hee-Chul**; 5-106, Eunma Apt., Daechi-dong, Gangnam-gu, Seoul 135-280 (KR). **KANG, Bok-Ki**; 108-203, Hanyang Apt., Gugal-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-736 (KR). **KIM, Jun-Ku**; 301-1005, Saeteomauel Moamiraedo Apt., Jukjeon-dong, Suji-gu, Yongin-si, Gyeonggi-do 448-160 (KR).

(74) Agent: **OH, Kook-Jin**; 302, Dooeon Bldg., 1708-6, Seocho-dong, Seocho-gu, Seoul 137-884 (KR).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING OLMESARTAN MEDOXOMIL AND ROSUVASTATIN OR ITS SALT



(57) Abstract: The present invention provides a pharmaceutical composition having a single dosage form comprising a compartment comprising olmesartan medoxomil; and a compartment comprising rosuvastatin or its salt, wherein said compartments are formulated in a separate form. In the pharmaceutical composition of the present invention, olmesartan medoxomil and rosuvastatin or its salt are formulated into a combination dosage form having separate compartments, thereby being able to solve the absorption-inhibition problem originated from drug interaction. In addition, the use of a certain disintegrant(s) makes it possible to obtain a combination formulation bioequivalent to the single formulation of each of drugs.

WO 2013/147462 A1